权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

International Collaboration for Application of Boron Neutron Capture Therapy to Intraoperative Irradiational Therapy

硼中子俘获疗法在术中放射治疗中应用的国际合作

基本信息

批准号：
11691202
负责人：
YANAGIE Hironobu
金额：
$ 29.68万
依托单位：
TEIKYO UNIVERSITY (2000-2001)The University of Tokyo (1999)
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (A)
财政年份：
1999
资助国家：
日本
起止时间：
1999 至 2001
项目状态：
已结题

项目摘要

We perform the international collaboration for appication of Boron Neutron capture Therapy(BNCT) to intraoperative irradiation thrapy of cancer.(1) We prepare a polyethylene-glycol (PEG) binding liposome entrapped ^<10>B compound for the delivery system. After thermal neutron irradiation of mice injected with ^<10>B-bare liposome or ^<10>B-PEG-liposome, AsPC-1 tumour growth was suppressed relative to controls. Injection of ^<10>B-PEG-liposome caused the greatest tumour suppression with thermal neutron irradiation in vivo.(2) We performed neutron capture autoradiography(NCAR) using CR-39 plastic track detectors. The CR-39 detectors attached with samples were exposed to thermal neutrons or cold neutrons at Rikkyo University, PSI, Institute of Jozef Stefan or Sakley Institute. We can increase the accumulation of ^<10>B atoms in the tumor tissues by PEG-liposome, which increase the retension in the blood flow and escape the phagocytosis by RES.(3) BNCT were performed to 64 brain tumor patients consisting of glioblastoma maltiforme(GBM) and anaplastic astrocytoma at Kyoto University Reactor. BNCT was superior to the standard therapy on survival rate in Japan. Two-year survival rates were superior to the outcome by standard treatment.(4) The BNCT group of pavia University, Italy, was performed the BNCT for isolated liver with multiple metastasis of colon cancer after perfusion of BPA. After BNCT the liver was reconnected to the patient. The outcome of the patient is still good in 7 months after operation.(5) Eighteen patients of GBM was performed the BNCT after drip infusion of BPA at reactor of Helsinki University, Finland. The average planning target dose of neutron and normal brain dose of neutron was 30〜61Gy and 3〜6 Gy, respectively. The total 1-year survival rate was 61%.

开展了硼中子俘获治疗（BNCT）在肿瘤术中放射治疗中的应用国际合作。(1)我们制备了聚乙二醇（PEG）结合脂质体包埋的β-<10>B化合物作为给药系统。在注射了μ <10>B-裸脂质体或μ <10>B-PEG-脂质体的小鼠的热中子照射后，相对于对照，AsPC-1肿瘤生长受到抑制。注射β<10>-B-PEG-脂质体引起体内热中子照射的最大肿瘤抑制。(2)我们使用CR-39塑料径迹探测器进行中子俘获放射自显影（NCAR）。在立教大学、PSI、约瑟夫·斯特凡研究所或萨克利研究所，将与样品相连的CR-39探测器暴露于热中子或冷中子。PEG<10>-脂质体可以增加肿瘤组织中的B原子的聚集，从而增加血流的滞留，逃避RES的吞噬。(3)对京都大学反应堆的64例脑肿瘤患者进行了BNCT检查，包括恶性胶质母细胞瘤（GBM）和间变性星形细胞瘤。在日本，BNCT的生存率上级优于标准治疗。2年生存率上级优于标准治疗的结果。(4)意大利帕维亚大学的BNCT组，在BPA灌注后对结肠癌多发转移的离体肝脏进行BNCT。BNCT后，肝脏重新连接到患者。术后7个月患者的预后仍然良好。(5)18例GBM患者在芬兰赫尔辛基大学的反应器中滴注BPA后进行了BNCT。中子平均计划靶剂量为30 × 61戈伊，中子平均正常脑剂量为3 × 60戈伊。总的1年生存率为61%。